Blood test could predict cancer worsening in rare blood disorders

NCT ID NCT04942080

Recruiting now Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether changes in the level of a specific gene mutation (CALR) in the blood can help predict when certain blood cancers (myeloproliferative neoplasms) get worse. Researchers will collect blood samples from 260 adults diagnosed between 2006 and 2020 and track mutation levels over time. The goal is to see if these levels can serve as an early warning sign of disease progression, without testing any new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors use CALR mutation levels as a warning sign to detect disease worsening earlier in patients with certain blood cancers.
What could go wrong: This is an observational study, not a treatment trial. It may not lead to any change in patient care, and results might not apply to all patients with these conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cellular phase chronic idiopathic myelofibrosis essential thrombocythemia Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis thrombocytosis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL THROMBOCYTHEMIA MYELOPROLIFERATIVE NEOPLASM PRIMARY MYELOFIBROSIS, FIBROTIC STAGE PRIMARY MYELOFIBROSIS, PREFIBROTIC STAGE

Contacts and locations

Locations

AP-HP Henri Mondor
RECRUITING

Paris, 94010, France
CHU Angers
RECRUITING

Angers, France
Ch Cholet
RECRUITING

Cholet, 49300, France
Ch Le Mans
RECRUITING

Le Mans, 72037, France
Ch Morlaix
RECRUITING

Morlaix, 29672, France
Ch Quimper
RECRUITING

Quimper, 29107, France
Chu Bordeaux
RECRUITING

Bordeaux, 33604, France
Chu Brest
RECRUITING

Brest, 29200, France
Chu Poitiers
RECRUITING

Poitiers, 86021, France
Chu Tours
RECRUITING

Tours, 37000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.